Literature DB >> 31048053

Direct Transcavernous Sinus Approach for Endoscopic Endonasal Resection of Intracavernous Sinus Tumors.

Qiuhang Zhang1, Zaixing Wang2, Hongchuan Guo3, Bo Yan3, Zhenlin Wang3, Hailiang Zhao2, Ronald Sahyouni4, Edward C Kuan4.   

Abstract

OBJECTIVE: Because of its vascular supply and neurovascular contents, the cavernous sinus (CS) is a challenging area to dissect in the setting of skull base tumors with intracavernous extension or invasion. In the present study, we report the clinical outcomes of 14 patients with tumors with CS invasion that were surgically treated using a direct transcavernous sinus approach for endoscopic endonasal resection of their intracavernous sinus tumors.
METHODS: Fourteen patients had undergone surgery using a direct endoscopic endonasal transcavernous sinus approach. The pathologic entities included Knosp grade 3-4 pituitary adenomas (n = 8), meningioma (n = 3), squamous cell carcinoma (n = 2), and chondrosarcoma (n = 1). The indications, surgical technique, and outcomes are discussed.
RESULTS: Gross total resection was achieved in 11 patients (78.6%). All patients experienced resolution or improvement of symptoms. One patient experienced a transient oculomotor nerve palsy, which had resolved within 2 months postoperatively. No other complications occurred. For those tumors that had been grossly resected, no recurrence developed in any patient (mean follow-up, 40.4 ± 24.8 months; range 10-84).
CONCLUSIONS: Depending on the space created by intracavernous sinus tumors, use of the transanterior wall for the CS approach in endoscopic endonasal surgery could adequately treat most patients in our case series. This approach provided good visualization of the CS and can be used to treat tumors with favorable outcomes and a low incidence of complications in appropriately evaluated patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cavernous sinus; Endoscopic endonasal surgery; Pituitary tumors; Sella and parasellar tumors; Skull base

Mesh:

Year:  2019        PMID: 31048053     DOI: 10.1016/j.wneu.2019.04.182

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

Review 1.  Modern endoscopic skull base neurosurgery.

Authors:  Rafael Martinez-Perez; Luis C Requena; Ricardo L Carrau; Daniel M Prevedello
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

2.  The endonasal midline inferior intercavernous approach to the cavernous sinus: technical note, cadaveric step-by-step illustration, and case presentation.

Authors:  Rima S Rindler; Luciano C Leonel; Stephen Graepel; Edoardo Agosti; Panagiotis Kerezoudis; Carlos D Pinheiro-Neto; Maria Peris-Celda
Journal:  Acta Neurochir (Wien)       Date:  2022-06-23       Impact factor: 2.816

3.  Combined endoscopic endonasal and transorbital multiportal approach for complex skull base lesions involving multiple compartments.

Authors:  Won-Jae Lee; Sang Duk Hong; Kyung In Woo; Ho Jun Seol; Jung Won Choi; Jung-Il Lee; Do-Hyun Nam; Doo-Sik Kong
Journal:  Acta Neurochir (Wien)       Date:  2022-04-29       Impact factor: 2.816

Review 4.  Sarcomas of the sellar region: a systematic review.

Authors:  Fernando Guerrero-Pérez; Noemi Vidal; Macarena López-Vázquez; Reinaldo Sánchez-Barrera; Juan José Sánchez-Fernández; Alberto Torres-Díaz; Nuria Vilarrasa; Carles Villabona
Journal:  Pituitary       Date:  2021-02       Impact factor: 4.107

Review 5.  Midline Skull Base Meningiomas: Transcranial and Endonasal Perspectives.

Authors:  Ciro Mastantuoni; Luigi Maria Cavallo; Felice Esposito; Elena d'Avella; Oreste de Divitiis; Teresa Somma; Andrea Bocchino; Gianluca Lorenzo Fabozzi; Paolo Cappabianca; Domenico Solari
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

6.  Superior turbinate management and olfactory outcome after endoscopic endonasal transsphenoidal surgery for pituitary adenoma: a propensity score-matched cohort study.

Authors:  Pu Li; Kai Luo; Qiuhang Zhang; Zhenlin Wang
Journal:  Int Forum Allergy Rhinol       Date:  2020-09-16       Impact factor: 3.858

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.